MX2014005183A - Anticuerpos anti-kdr y metodos de uso. - Google Patents

Anticuerpos anti-kdr y metodos de uso.

Info

Publication number
MX2014005183A
MX2014005183A MX2014005183A MX2014005183A MX2014005183A MX 2014005183 A MX2014005183 A MX 2014005183A MX 2014005183 A MX2014005183 A MX 2014005183A MX 2014005183 A MX2014005183 A MX 2014005183A MX 2014005183 A MX2014005183 A MX 2014005183A
Authority
MX
Mexico
Prior art keywords
methods
kdr
variety
kdr antibodies
antibodies
Prior art date
Application number
MX2014005183A
Other languages
English (en)
Other versions
MX356412B (es
Inventor
Yongke Zhang
Guo-Liang Yu
Weimin Zhu
Yaohuang Ke
Sum Wai Pierre Lee
Original Assignee
Apexigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apexigen Inc filed Critical Apexigen Inc
Publication of MX2014005183A publication Critical patent/MX2014005183A/es
Publication of MX356412B publication Critical patent/MX356412B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona los anticuerpos monoclonales anti-KDR y las composiciones relacionadas, que pueden ser utilizadas en cualquiera de una variedad de métodos terapéuticos para el tratamiento de una variedad de cánceres, artritis reumatoide, retinopatía diabética y otros trastornos asociados con la expresión y/o actividad aberrantes de VEGF o KDR.
MX2014005183A 2011-11-02 2012-11-01 Anticuerpos anti-kdr y metodos de uso. MX356412B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161554758P 2011-11-02 2011-11-02
US201261609581P 2012-03-12 2012-03-12
PCT/US2012/062929 WO2013067098A1 (en) 2011-11-02 2012-11-01 Anti-kdr antibodies and methods of use

Publications (2)

Publication Number Publication Date
MX2014005183A true MX2014005183A (es) 2014-06-05
MX356412B MX356412B (es) 2018-05-29

Family

ID=48192738

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005183A MX356412B (es) 2011-11-02 2012-11-01 Anticuerpos anti-kdr y metodos de uso.

Country Status (13)

Country Link
US (1) US9441042B2 (es)
EP (1) EP2785742B1 (es)
JP (1) JP6117225B2 (es)
KR (1) KR102027603B1 (es)
AU (1) AU2012318246B2 (es)
BR (1) BR112014010774A2 (es)
CA (1) CA2854153A1 (es)
HK (1) HK1201537A1 (es)
IL (1) IL232383B (es)
MX (1) MX356412B (es)
RU (1) RU2014122184A (es)
TW (1) TWI571473B (es)
WO (1) WO2013067098A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013067098A1 (en) 2011-11-02 2013-05-10 Apexigen, Inc. Anti-kdr antibodies and methods of use
EA036257B1 (ru) * 2014-10-07 2020-10-20 КАДМОН КОРПОРЕЙШН, ЭлЭлСи Антитела человека против vegfr-2/kdr
KR101896882B1 (ko) * 2015-11-30 2018-09-11 앱클론(주) Vegfr2에 특이적으로 결합하는 항체
WO2018093668A1 (en) * 2016-11-16 2018-05-24 Eli Lilly And Company Therapy for metatastic colorectal cancer using anti-vegfr-2 and anti-vegf-d antibodies
US20210139589A1 (en) * 2017-06-22 2021-05-13 Apexigen, Inc Anti-vista antibodies and methods of use
CN114174335B (zh) * 2019-07-19 2023-12-15 神州细胞工程有限公司 一种人源化vegfr2抗体及其应用
BR112023018537A2 (pt) * 2021-04-14 2023-10-31 Suzhou Transcenta Therapeutics Co Ltd Anticorpos anti-hvegfr2

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
AU6796094A (en) 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5675063A (en) 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US20020064528A1 (en) 2000-01-28 2002-05-30 Zhenping Zhu Antibodies specific to KDR and uses thereof
US6627196B1 (en) * 1999-08-27 2003-09-30 Genentech, Inc. Dosages for treatment with anti-ErbB2 antibodies
SK15302002A3 (sk) 2000-03-31 2004-06-08 Imclone Systems Incorporated Antagonista receptora VEGFR a jeho použitie
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003213687A1 (en) 2002-03-04 2003-09-22 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2548817A1 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
KR100864549B1 (ko) 2004-08-04 2008-10-20 어플라이드 몰리큘라 에볼류션, 인코포레이티드 변이체 ｆｃ 영역
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
WO2006079372A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
CA2602663A1 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc variants with optimized properties
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
EP1973576B1 (en) 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
KR100883430B1 (ko) 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
WO2009013543A2 (en) 2007-07-25 2009-01-29 Astrazeneca Ab Targeted binging agents directed to kdr and uses thereof - 035
US20100317539A1 (en) 2009-06-12 2010-12-16 Guo-Liang Yu Library of Engineered-Antibody Producing Cells
US8293483B2 (en) * 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
WO2013067098A1 (en) 2011-11-02 2013-05-10 Apexigen, Inc. Anti-kdr antibodies and methods of use
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
WO2013067098A1 (en) 2013-05-10
AU2012318246A1 (en) 2013-06-06
RU2014122184A (ru) 2015-12-10
EP2785742A1 (en) 2014-10-08
KR102027603B1 (ko) 2019-10-01
JP2014532706A (ja) 2014-12-08
BR112014010774A2 (pt) 2017-06-13
HK1201537A1 (en) 2015-09-04
EP2785742B1 (en) 2020-01-08
MX356412B (es) 2018-05-29
IL232383B (en) 2020-05-31
AU2012318246B2 (en) 2015-10-15
KR20140091028A (ko) 2014-07-18
US20140377282A1 (en) 2014-12-25
JP6117225B2 (ja) 2017-04-19
CA2854153A1 (en) 2013-05-10
EP2785742A4 (en) 2016-02-17
TW201326211A (zh) 2013-07-01
TWI571473B (zh) 2017-02-21
IL232383A0 (en) 2014-06-30
US9441042B2 (en) 2016-09-13

Similar Documents

Publication Publication Date Title
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX342810B (es) Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MX356412B (es) Anticuerpos anti-kdr y metodos de uso.
PH12016501618A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
SG194701A1 (en) Anti-cd40 antibodies and methods of use
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
MX2014014085A (es) Anticuerpos e inmunoconjugados contra ly6e y metodos de uso.
UA115034C2 (uk) Імунокон'югат для застосування в лікуванні раку або запального порушення
MX356107B (es) Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
PH12015502788A1 (en) Antibody formulations and methods
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
NZ730763A (en) Methods of treating a tauopathy
EA201590174A1 (ru) Иммуноконъюгаты, содержащие анти-cd22 антитела
MY167920A (en) HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF
FR2975600B1 (fr) Agents pour le traitement de tumeurs
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
EA201890598A3 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
MX2021006111A (es) Composicion farmaceutica que comprende un anticuerpo anti-gm-csf para usarse en el tratamiento de artritis reumatoide.
MA40612A (fr) Nouveaux anticorps anti-mfi2 et méthodes d'utilisation
WO2016066634A3 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
MX2013002718A (es) Composiciones de anticuerpo anti-vegfr-3.
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.

Legal Events

Date Code Title Description
FG Grant or registration